Palisade Bio Announces Completion of Enrollment in LB1148 Dose Optimization Study

Palisade Bio, a biopharmaceutical company focused on gastrointestinal complications, has announced the completion of patient enrollment in its LB1148 dose optimization study. The study aims to generate valuable data on pharmacokinetics and pharmacodynamics across multiple doses in healthy adult volunteers. This milestone brings Palisade Bio closer to obtaining Phase 2 topline data for the preven..

  • format_list_bulleted BS
  • · 2023. 7. 6.
  • textsms

InnoCare Announces First Psoriasis Patient Dosed in Clinical Trial of TYK2 Allosteric Inhibitor ICP-488 in China

InnoCare Pharma (HKEX: 09969; SSE: 688428) has announced that the first psoriasis patient has been dosed in a clinical trial of their TYK2 allosteric inhibitor ICP-488 in China. The phase I clinical trial has already completed single ascending doses (SAD) and multiple ascending doses (MAD) of ICP-488, showing a well-tolerated safety profile. The ongoing study aims to evaluate the safety and effi..

  • format_list_bulleted BS
  • · 2023. 7. 6.
  • textsms

New Dosing Schedule for Ropeginterferon Alfa-2b Shows Improved Efficacy in Polycythemia Vera

New ropeginterferon alfa-2b Data Suggest Alternate Dosing Schedule May Achieve Greater and Quicker Complete Hematologic and Molecular Responses in Polycythemia Vera PharmaEssentia Corporation (TPEx:6446), a leading fully integrated biopharmaceutical company in Taiwan, announced today the publication of new results from a Phase 2 clinical study with ropeginterferon alfa-2b, marketed as BESREMi®, ..

  • format_list_bulleted BS
  • · 2023. 7. 2.
  • textsms

First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation

First Wave BioPharma, a clinical-stage biopharmaceutical company specializing in gastrointestinal (GI) diseases, has announced that the final patient has been dosed in the Phase 2 SPAN clinical trial. The trial is investigating an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in cystic fibrosis (CF) patients. Topline..

  • format_list_bulleted BS
  • · 2023. 6. 29.
  • textsms

First Wave BioPharma Strengthens Intellectual Property Estate

First Wave BioPharma, a clinical-stage biopharmaceutical company specializing in gastrointestinal (GI) diseases, has announced the publication of two patent applications for its enhanced enteric microgranule delivery formulation of adrulipase. The patents cover composition of matter and methods of use claims and were published by both the United States Patent and Trademark Office (USPTO) and the..

  • format_list_bulleted BS
  • · 2023. 6. 28.
  • textsms

GSK Shares Positive Data for AREXVY, its Respiratory Syncytial Virus (RSV) Older Adult Vaccine, Indicating Protection Over Two RSV Seasons

GSK has announced positive results from its clinical trial of AREXVY, a vaccine for respiratory syncytial virus (RSV) in older adults. The AReSVi-006 phase III trial found that the vaccine provided protection against RSV-lower respiratory tract disease and severe disease over two full RSV seasons, including in participants with underlying medical conditions. Safety and reactogenicity data were c..

  • format_list_bulleted BS
  • · 2023. 6. 22.
  • textsms

PDS Biotechnology Announces Achievement of Efficacy Threshold in Stage 2 of the VERSATILE-002 Trial Evaluating PDS0101 and KEYTRUDA® in Head and Neck Cancer

PDS Biotechnology has achieved the efficacy threshold in Stage 2 of the VERSATILE-002 trial with PDS0101 and KEYTRUDA® for head and neck cancer. The trial evaluates PDS0101, an HPV-targeted immunotherapy, combined with Merck’s anti-PD-1 therapy for the treatment of unresectable, recurrent or metastatic human papillomavirus (HPV)16-positive head and neck cancer. Fourteen patients in the immune ch..

  • format_list_bulleted BS
  • · 2023. 6. 15.
  • textsms

U.S. FDA Approves Bylvay® for Patients Living with Cholestatic Pruritus Due to Alagille Syndrome

Ipsen has received approval from the US Food and Drug Administration (FDA) for Bylvay, a drug used to treat cholestatic pruritus in patients with Alagille syndrome aged 12 months or older. This marks the second rare cholestatic liver disease indication for Bylvay in the US after progressive familial intrahepatic cholestasis related pruritus in 2021. The approval was based on positive data from t..

  • format_list_bulleted BS
  • · 2023. 6. 14.
  • textsms

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

Vaccitech, a clinical-stage biopharmaceutical company, has announced the dosing of the first patient in its PCA001 clinical trial. The study is designed to determine the efficacy and safety of VTP-850 monotherapy in men with rising PSA after definitive local therapy for prostate cancer. VTP-850 is a next-generation immunotherapeutic candidate that uses two proprietary non-replicating viral vecto..

  • format_list_bulleted BS
  • · 2023. 6. 13.
  • textsms